Our question of the week: How do you anticipate the availability of Rezdiffra will affect your work related to Mash and MASLD? ๐๐ฒ๐ฝ๐ฎ๐๐ผ๐น๐ผ๐ด๐ถ๐๐๐: when will you start prescribing it and for what kind of patients? ๐๐ป๐ฑ๐ผ๐ฐ๐ฟ๐ถ๐ป๐ผ๐น๐ผ๐ด๐ถ๐๐๐ ๐ฎ๐ป๐ฑ ๐ฃ๐ฟ๐ถ๐บ๐ฎ๐ฟ๐ ๐๐ฎ๐ฟ๐ฒ: do you anticipate educating and screening more patients? And when you screen what test will use? ๐๐น๐ถ๐ป๐ถ๐ฐ๐ฎ๐น ๐ฅ๐ฒ๐๐ฒ๐ฎ๐ฟ๐ฐ๐ต๐ฒ๐ฟ๐: how might this affect the research that you do or the funds available to do it? And finally, for ๐ฃ๐ฎ๐๐ถ๐ฒ๐ป๐ ๐๐ฑ๐๐ผ๐ฐ๐ฎ๐๐ฒ๐: how will this affect your ability to advocate and educate? Send your answers to ๐พ๐๐ฒ๐๐๐ถ๐ผ๐ป๐@๐ฆ๐๐ฟ๐ณ๐ถ๐ป๐ด๐ ๐๐ฆ๐.๐ฐ๐ผ๐บ and we'll put them in the podcast.
#SurfingMASH #questionoftheweek #QoW #fattyliverdisease
โHi, this is Roger Green, host of the Surfing the MASH Tsunami Podcast. We've had a change in plans for this week, so I just wanted to share it with you so you could know what you're going to be listening for. The plan originally was to put an episode with payers today, but the new Semaglutide Wegovy indication on Friday, coupled with the upcoming resmetirom PDUFA scrambled a couple of people we wanted off our call, we'll get them back when we can. So we will not have an episode today, but on Thursday we will have an episode with U.S. KOLs reacting to the resmetirom decision, and on Friday with another group of KOLs from the U.S. and abroad, and on Monday with patient advocates. That's three episodes over the span of five days.
We plan to be posting on Friday, on Saturday, we'll have conversation Sunday, Monday, and the third episode out on Wednesday. So reserve a lot of time for us starting on Friday, in addition to all the other excitement in your life, and I look forward to seeing you soon. Until then, stay safe, surf on, bye-bye now.โ
#SurfingMASH #fattyliver #resmetirom #PDUFA #Semaglutide
On this episode, Zobair Younnosi and the crew talked about the need to raise awareness of MAFLD and MASH in all its different elements, and what it means in different countries around the world. What is one thing that you can do, that is not part of your
Email us your answer at ๐พ๐๐ฒ๐๐๐ถ๐ผ๐ป๐@๐๐๐ฟ๐ณ๐ถ๐ป๐ด๐ ๐๐ฆ๐.๐ฐ๐ผ๐บ
On this episode, Zobair Younnosi and the crew talked about the need to raise awareness of MAFLD and MASH in all its different elements, and what it means in different countries around the world. What is one thing that you can do, that is not part of your day job, that will have the effect of increasing awareness or helping people with disease?
#SurfingMASH #MASLD #MASH #FattyLiver #QuestionOfTheWeek
February 7 March Updates From Roger Green
February 7 March Updates From Roger Green, Executive Producer and Host of the Surfing the MASH Tsunami podcast.
โAs I announced earlier this week, we'll be back on February 7th for a full weekly schedule, at least, of 2024 episodes. I wanted to tell you a little bit about what's coming in February and March. February 7th simply starts with us, Louise Campbell and Jรถrn M. Schattenberg, talking about their interesting experiences the past few months. Hopefully to have a guest with us to talk about hers or his. I don't have that much to talk about, but I'll do a little.
Next four weeks up until March 14th will be a look at 2024 from different perspectives, including NITs, drug development other than resumeterone, clinical care pathway development, epidemiology payers. We're still working on the specifics. But one specific exciting event will be on February 21st, when most of the key players in developing the new nomenclature will be joining us to talk about how things are going now, what they've learned, and what we have to look forward to in 2024.
So, until then, have a great time. Stay safe. Surf on. I look forward to seeing you in two weeks on February 7th, and can't wait to get back to Podcasting Weekly. Bye bye now.โ
#fattyliverpodcast #MASLD #MASH
Update From Roger Green
From Roger Green, Executive Producer and Host of the Surfing the Mesh Tsunami podcast.
โI wanted to let you know that despite being down for the month of January, we are returning with regular weekly episodes for all of 2024, starting on February 7th, first posting. We'll be covering lots of exciting things over the year. We'll have one new feature coming in mid-February that I'll be announcing for the first time on the 7th.
And I wanted to let you know that our transition to SurfingMash.com is complete. You can send emails to questions@ info@ or roger.green@ and we'll receive them.
I'll have another post coming later in the week about some of what you have to look forward to in the next two months, but for now I just want to let you know we'll be back, circle the date on your calendar, and every Wednesday evening after that. Take care, surf on, stay safe, we'll see you on the podcast starting February 7th. Bye bye now.โ
#surifngMASH #fattyliverpodcast #podcast #MAFLD
We just received our 2023 year-end numbers from Spotify. They're pretty dazzling, and we wanted to share them with our LinkedIn followers first! In 2023, Spotify listenership increased by 50% Our listeners shared our episodes and conversations with frien
We just received our 2023 year-end numbers from Spotify. They're pretty dazzling, and we wanted to share them with our LinkedIn followers first!
In 2023, Spotify listenership increased by 50%
Our listeners shared our episodes and conversations with friends and colleagues, with 46% sharing via direct link, 41% via text link and 11% via WhatsApp.
Most exciting to us, Spotify counts the number of listeners who consider us a "Top" podcast. If we extrapolate Spotify's percent of downloads to the entire audience, we estimate that 3,000 people consider Tsunami a Top Ten podcast, 2,000 consider Tsunami a Top Five podcast, and 750 consider us their Top podcast!
Thanks for being loyal listeners and supporters. We'll have another post tomorrow about our year-end interviews and plans for 2024.
Until then, stay safe, surf on and enjoy your holidays, whichever ones you celebrate!
#surfingNASH #surfingMASH #fattyliverpodcast #NAFLD
Wishing our amazing producer and host, Roger Green a very happy birthday!
One of our team members has a very vocal pup! Tucker loves to sing, collects rocks, and chase squirrels.
#singingdog #happybirthday
Hi! This is Roger Green, Executive Producer and co-Host of the Surfing the NASH Tsunami podcastโฆ
Hi! This is Roger Green, Executive Producer and co-Host of the Surfing the NASH Tsunami podcastโฆ
Hi! This is Roger Green, Executive Producer and co-Host of the Surfing the NASH Tsunami podcast. We are not posting our EASL Congress 2023 summary tonight, as originally promised. Our reason is simple: too much content. We didnโt want to post a single e
Hi! This is Roger Green, Executive Producer and co-Host of the Surfing the NASH Tsunami podcast. We are not posting our EASL Congress 2023 summary tonight, as originally promised.
Our reason is simple: too much content. We didnโt want to post a single episode with several disconnected thoughts, nor did we want to focus on only a single topic...so hereโs what we will do.
Over the weekend, we will post excerpts from our real-time coverage and perhaps preview or previous year conversations as well. Instead, we will run four consecutive weeks of podcasts on what we learned from the EASL Congress 2023. Next Wednesday, Stephen Harrison and Mazen Noureddin will join us to discuss some of the major drug development themes and presentations from the meeting. Over the rest of July and first week of August, our weekly sessions will cover four other topics relying heavily on presentations and posters from the EASL Congress: โArtificial Intelligence; โ basic liver science; non-invasive diagnostics and clinical care pathways.
We are firming up guests and schedules for the following four weeks. We will announce what we are posting at least one week ahead. One more topic: we are working on rebranding the podcast to align with the new nomenclature. You may be invited to a bulletin board to discuss this issue, or perhaps some marketing research to help guide us. We expect to release our new name and brand by the end of July. Enjoy this weekendโs conversations and the episodes to come...and, whatever else you do, stay safe and surf on!
Our weekly episode will post tomrrow, and we thank you for your patience. In the meantime, please enjoy this relaxing video of and an overhead view of the beach. You deserve a break too. #meditation #mindfullness
Our weekly episode will post tomorrow, and we thank you for your patience. In the meantime, please enjoy this relaxing video of and an overhead view of the beach. You deserve a break . #meditation #mindfullness
We are gearing up for our coverage of the upcoming NASH-TAG event. Follow us here and subscribe to our website for up-to-date announcements on SurfingNASHโขCom coverage of NASH-TAG 2023 #fattyliver #nashpodcast #NASHTAG2023
We are gearing up for our coverage of the upcoming NASH-TAG event. Follow us here and subscribe to our website for up-to-date announcements on SurfingNASHโขCom coverage of NASH-TAG 2023 #fattyliver #nashpodcast #NASHTAG2023
Congratulations to Madrigal Pharmaceuticals
SurfingNASH .com congratulates Madrigal Pharmaceuticals on the release of successful efficacy and safety results from the MAESTRO-NASH Phase 3 clinical trial!
We have gathered a varied set of stakeholders for a special recording session this afternoon discussing these results and what they mean for the range of NAFLD stakeholders.
Watch here for more information about when tonight or tomorrow morning we will be releasing the episode. It should be a good one!
#madrigal #surfingNASH #clinicaltrials #maestronash #phase3
https://bit.ly/Histoindex-AI-Extrasode S3-E14.5 - Improving Ballooned Hepatocyte Analysis Through Artificial Intelligence How Can an Informed Application of Artificial Intelligence Improve Ballooned Hepatocyte Identification and Analysis in Advanced Fibr
https://bit.ly/3tclIWc
S3-E14.5 - Improving Ballooned Hepatocyte Analysis Through Artificial Intelligence
How Can an Informed Application of Artificial Intelligence Improve Ballooned Hepatocyte Identification and Analysis in Advanced Fibrosis and Cirrhosis?
#NASH #NAFLD #Histopathology #NASHClinicalTrialFailures #PlaceboResponseRates #BalloonedHepatocytes #HistoIndex #ArtificialIntelligence #qBallooning2 #qFibrosis #SNOFscore #portalhypertension #varices Histoindex Pte Ltd Galectin Therapeutics @Dean Tai
NASH-TAG 2022 - Day 2
S3-E3 โ NASH-TAG 2022 Day Two: Weight loss, Innovative Approaches and the Fireside Chat on Testing Methods
MORE: https://bit.ly/NASH-TAG-2022-Day-2
The Surfers and "fifth Beatle" Jรถrn Schattenberg review the highs, lows and powerful moments of Day Two at NASH-TAG 2022.
Hosts and Guests: Roger Green, Stephen Harrison, Louise Campbell, Prof Dr. Jรถrn M. Schattenberg
Sessions Covered:
โข New Data on Biomarkers, Combination Therapy, Predictive Imaging
โข Novel genetic markets
โข Innovative treatment approaches
โข Basic Science and Unmet Needs in NASH Fibrosis
โข Lessons Learned from Early Pioneers
โข Fresh examinations of endpoints and NIT use in cirrhotic and non-cirrhotic patients
NASH-TAG 2022 Day 1
S3-E2 - NASH-TAG 2022 Day 1 Summary: NASH Combination Therapies, Artificial Intelligence, Basic Science - SurfingNASH is covering each day of NASH-TAG 2022. This episode includes two separate conversations, with Stephen Harrison, Louise Campbell, Mazen Noureddin, MD, MHSc, and Quentin M. Anstee in the first and Donna Cryer and Scott Friedman in the second.
Epsiode Sponsored By DiaPharma
MORE: https://bit.ly/NASH-TAG-2022-Day-1
โข Michael Charltonโs Year in Review Speech
โข Discussion on Clinical Trial Results: FXR agonists, aldafermin (FGF-19 agonist), FGF-21 agonists
โข Summary of Congress presentations on drugs in development
โข Basic biologic lessons: Phages, lipotoxicity, NASH HCC, organizes
โข Updates from the consortia: NIMBLE, LITMUS, Cirrhosis Network
โข Focus on AI: data on PathAI and HistoIndex, whatโs next for AI
Featuring The Following Host and Guests:
Roger Green
Host & Producer
Dr. Stephen Harrison
NASH-TAG Founder
Louise Campbell MSc AP
Tawazun Health
Mazen Noureddin
Cedars-Sinai Medical Center
Donna R. Cryer, JD
Global Liver Institute
Quentin M. Anstee
Newcastle University
Scott L. Friedman, MD
Icahn School of Medicine
2021 - NASH - Year In Review
Did you miss the SurfingNASH year-end interviews? You missed something special!
From December 22 through January 3, Surfing the NASH Tsunami posted interviews Louise Campbell and Roger Green held with 9 Key Stakeholders whose work pushed #NAFLD and #NASH knowledge, diagnosis and treatment forward in 2021. As the New Year is kicking into full swing, take one more look at this list to be certain you haven't missed something you really should hear.
โ Mazen Noureddin, MD, MHSc Noureddin discussed the role of AI in histopathology
โ Alina Allen discussed MRE and the broad view of NITs
โ Wayne Eskridge discussed the first study sponsored by a patient advocate group to appear in a refereed publication
โ Manal Abdelmalek discussed cirrhosis treatment strategies today and upcoming drug development
โ Kenny Cusi discussed efforts to create a multidisciplinary clinical care pathway
โ Prof. Dr. Jรถrn M. Schattenberg discussed cost effectiveness of NASH therapy and impact on quality-of-life
โ Stephen Harrison discussed five major themes of 2021
โ Jeffrey V. Lazarus discussed the global effort to advance a NAFLD Public Health Agenda
โ Andrew Scott discussed the trends and actions bring patient advocacy into the heart of the NAFLD discussion
Pfizer, Merck, Madrigal Pharmaceuticals, Inventiva Pharma, Akero Therapeutics, bio89, Viking Therapeutics, Inc., Hepion Pharmaceuticals, Terns Pharmaceuticals, North Sea Therapeutics, High Tide Inc. Therapeutics, Novo Nordisk, Eli Lilly and Company, Boehringer Ingelheim, Siemens Healthineers, Echosens, Sonic Incytes Medical Corp. Medical Corporation, E-Scopics, Nordic Bioscience A/S, Labcorp, GENFIT, Perspectum Ltd., Resoundant, Antaros Medical, ChronWell, Inc.,
Join us for AASLD 2021!
Click here to join the conversation! https://bit.ly/Call-In-AASLD-2021-Surfing-NASH
๏ฟผDo you have something to say about AASLD 2021?
We are scheduling "call-ins" to join us for our live recordings for our coverage of AASLD.
#aasld2021 #LiverMTG21 #fattyliverdisease
S2-E53 Join SurfingNASH to Preview AASLD 2021
S2-E53 Join SurfingNASH to Preview AASLD 2021
AASLD 2021 starts next Friday with 68 "Meet the Experts" sections, 36 parallel tracks, 12 late-breaker presentations and a variety of SIGs, abstract tours and major speeches . Join SurfingNASH to discuss meeting elements related to NAFLD and NASH. These are not limited to sections with NAFLD or NASH in the title, but include other sections that will shed light on important issues in diagnosis and management of Fatty Liver Disease. SurfingNASH.com
MORE: https://bit.ly/Previewing-AASDL-2021
#AASLD #NASH #NAFLD #fattyliver
NASH imaging for the future! Know these phrases!
๐ก๐๐ฆ๐ ๐ถ๐บ๐ฎ๐ด๐ถ๐ป๐ด ๐ณ๐ผ๐ฟ ๐๐ต๐ฒ ๐ณ๐๐๐๐ฟ๐ฒโ ๐๐ป๐ผ๐ ๐๐ต๐ฒ๐๐ฒ ๐ฝ๐ต๐ฟ๐ฎ๐๐ฒ๐โ
In Episode 50, Lars Johansson, Chief Scientific Officer at Antaros Medical, discussed imaging techniques that can help us identify therapies that maximize the numbers of functioning hepatocytes for different kinds of patients. Some are available now, some only in clinical design.
Listen to Episode 50 to learn more about these techniques and the value they can bring:
https://bit.ly/Surfing-NASH-S2-E50
Antaros Medical, Echosens, Sonic Incytes Medical Corp., Madrigal Pharmaceuticals, Terns Pharmaceuticals, Akero Therapeutics, 89bio, Inventiva Pharma, GENFIT, Labcorp, Siemens Healthineers, Nordic Bioscience A/S, Perspectum Ltd., DiaPharma, Hepion Pharmaceuticals, HighTide Therapeutics, Merck, Pfizer, AbbVie, Novartis, Boston Pharmaceuticals, Novo Nordisk, Eli Lilly and Company, Boehringer Ingelheim, AstraZeneca, Resoundant, Galectin Therapeutics, CymaBay Therapeutics, Intercept Pharmaceuticals, Zydus Cadila Healthcare Limited , ONEGENE AMERICA INC, Gilead Sciences, Sagimet Biosciences, E-Scopics, Theratechnologies Inc.
